natgillin/translations-raw huggingface dataset:
The mouse cell of claim 5, wherein the mouse cell comprises a single rearranged human light chain V/J gene sequence. 
Mišja stanica prema patentnom zahtjevu 5, naznačena time, što mišja stanica sadrži jednu sekvencu preuređenog humanog lakog lanca V/J.
The method according to any one of claims 1 to 3, wherein the X-ray powder diffraction pattern comprises peaks at 4.99, 15.12, 17.61, 17.77, 18.17, 20.28, 21.14, 21.64, 23.23 and 27.66 degrees 2Θ (±0.1 degrees 2Θ), wherein said X-ray powder diffraction pattern is made using CuKa1 radiation. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da uzorak difrakcije praha X-zraka obuhvaća vršne vrijednosti na 4,99, 15,12, 17,61, 17,77, 18,17, 20,28, 21,14, 21,64, 23,23 1 27,66 stupnjeva 20 (+ 0,1 stupanj 20), pri čemu se navedeni uzorak difrakcije praha X-zraka dobiva uporabom CuK.,-radijacije.
However, the preferred embodiment of the invention is to provide a pre-formed body of magnetic material and to apply the surface irregularities, representing indicia, afterwards in accordance with the specific requirements of use. 
Međutim, poželjnim utjelovljenjem predmetnog izuma želi se omogućiti unaprijed oblikovano tijelo magnetskog materijala na koje se nakon toga nanose površinske nepravilnosti koje predstavljaju oznaku, sukladno konkretnim zahtjevima uporabe.
The method according to claim 14, wherein the cancer is selected from lung cancer, squamous cell carcinoma, liver cancer, kidney cancer, breast cancer, colon cancer, colorectal cancer, and prostate cancer. 
uporabu u liječenju raka pri čemu je rak odabran od raka pluća, posebice raka pluća nemalih stanica, raka pločastih stanica, raka jetre, raka bubrega, raka dojke, raka debelog crijeva, kolorektalnog raka, raka prostate; ili
iv-b) a solid oral dosage form comprising about 150 mg vildagliptin free base, or a respective amount of a pharmaceutically acceptable salt thereof, and a carrier medium, said dosage form providing an arithmetic mean Cmax of vildagliptin of 272 ng/ml +/- 111 ng/ml following oral administration of said dosage form, on day 9 in a patient treated with said dosage form once a day since day 1 and wherein said patient has been served an ADA breakfast within 30 minutes of the morning administration of said dosage form (day 9 of the above described study), and/or 
Vildagliptina od 272 ng/mL +/- 111 ng/mL nakon oralne primjene navedenog dozirnog oblika na dan 9 pacijentu koji je bio tretiran navedenim dozirnim oblikom jednom dnevno od dana 1 i pri čemu je navedenom pacijentu bio serviran ADA doručak unutar 30 minuta jutarnje primjene navedenog dozirnog oblika, i/ili kruti oralni dozirni oblik koji sadrži oko 150 mg vildagliptin slobodne baze ili odgovarajuću količinu njegove farmaceutski prihvatljive soli, te podlogu, pri čemu navedeni dozirni oblik pruža srednju vrijednost Cmax.
The composition of item 1 or 2, wherein the extranodal lymphoma includes central nervous system (CNS), cutaneous tissue, breast, lungs, liver, gastrointestinal tract, genitourinary tract, ocular tissue, bone marrow and/or bones. 
Pripravak namijenjen upotrebi u skladu s patentnim zahtjevom 1 ili 2, naznačen time što ekstranodalni limfom zahvaća središnji Živčani sustav (CNS), kutano tkivo, dojke, pluća, jetru, gastrointestinalni sustav, genitourinarni sustav, očno tkivo, koštanu srž i/ili kosti.
When performing the information-increasing type of mapping, the base station apparatus can transmit, to a mobile station apparatus, a RRC signaling including information indicating the minimum amount and/or the maximum amount of resources in which the reception quality information can be mapped. 
Mobilni komunikacijski sustav prema zahtjevu 1, naznačen time da uređaj bazne stanice (100) dodano prenosi, na uređaj mobilne stanice (200), RRC signalizaciju koja sadrži informacije koje ukazuju na unaprijed definiranu količinu resursa u kojima se mogu mapirati informacije o kvaliteti prijema.
The method according to claim 17, further comprising the step of extending said multi-room building in a vertical direction such that each part of the building, provided according to the method of any one of claims 1 to 16, of a specific floor is vertically aligned with the underlying part of the building. 
Postupak sukladno zahtjevu 17, nadalje sadrži korak proširenja navedene višekatne zgrade na način da svaki dio zgrade, omogućen sukladno postupku iz bilo kojeg od zahtjeva 1 do 16, specifičnog poda vertikalno nagnutog s predležećim dijelom.
After 0.5 h, the solution was cooled to RT and 1N HCl solution was added until the reaction was acidic. 
Nakon pola sata otopina je ohlađena na sobnu temperaturu i dodana je IN otopina HCI sve dok reakcijska smjesa nije zakiseljena.
A biofertilizer composition, comprising psychrophilic: bacterial strains isolated from rhizosphere of Deschampsia antarctic a, wherein the composition contains one or more bacterial strains selected from the group consisting of Pseudomonas antarctica DaBact TI-9 (ATCC designation PTA8990), Pseudomonas trivialis DaBact 2H (ATCC designation PTA8988) and Arthrobacter ssp. 
PATENTNI ZAHTJEVI Smjesa bio gnojiva koja sadrži psihrofilne sojeve bakterija izolirane iz rizosferne antarktičke trave, naznačena time da ta smjesa sadrži jedan ili više sojeva bakterija odabranih iz skupine koju sačinjavanju Pseudomonas antarctica DaBact TI-9 (ATCC oznaka _PTA8990), Pseudomonas trivialis DaBact 2H (ATCC oznaka_PTA8988) 1 Arthrobacter ssp.
The composition according to claim 6, wherein the binder is selected from the group consisting of hydroxypropyl methylcellulose, hydroxypropylcellulose, maltodextrin, polyvinylpyrrolidone and microcrystalline cellulose. 
Pripravak u skladu patentnim zahtjevom 8, naznačen time, da se vezivo bira između hidroksipropil metilceluloze, hidroksipropilceluloze, maltodekstrina, polivinilpirolidona i / ili mikrokristalne celuloze.
The solvent was evaporated off and ethyl acetate (25 mL) was added. 
Otapalo je upareno i dodan je etil acetat (25 mL).
A 1st aspect concerns an apparatus for manufacturing hollow elongated bodies, optionally tapered poles, made of reinforced synthetic resin: 
Uređaj za proizvodnju šupljih izduljenih tijela, moguće sužavajućih štapova, načinjenih od ojačane sintetske smole, koji ima:
A mixture of this crude product and ammonium acetate (92.3 g) in ethanol (600 ml) was heated under reflux for 1 hour, allowed to cool to room temperature, and treated with methyl 2-(2-chlorobenzylidene)acetoacetate (286.6 g). 
Smjesa ovog sirovog proizvoda i amonij-acetata (92,3 g) u etanolu (600 ml) zagrijava se pod refluksom 1 sat, pusti se da se ohladi na sobnu temperaturu i tretira se s metil 2-(2-klorobenziliden)-acetoacetatom (286,6 g).
Use of (b) an antagonist of M3 muscarinic receptors as defined in claim 1 or 2 for the preparation of a medicament, for simultaneous, concurrent, separate or sequential use in combination with (a) a corticosteroid for the treatment of a respiratory disease which responds to M3 antagonism in a patient. 
Pakiranje, naznačeno time, da se sastoji od (b) antagonista M3 muskarinskih receptora kako je definiran u patentnom zahtjevu 1 ili 2 i (a) kortikosteroida kako je definiran u bilo kojem od patentnih zahtjeva 1 i 3 do 6 za istovremenu, istodobnu, odijeljenu i uzastopnu uporabu za liječenje ljudi i životinja koji pate ili su podložni dišnim bolestima kako je definirano u patentnom zahtjevu 10 ili 11.
at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of at least 1,000,000; and at least one polyethylene oxide having, based on rheological measurements, an approximate molecular weight of less than 1,000,000. 
(1) najmanje jedan polietilen oksid koji ima, prema reološkim mjerenjima, približnu molekularnu težinu od najmanje 1,000,000; i (2) 60 mg ili 80 mg oksikodon hidroklorida; 1 pri čemu pripravak sadrži barem oko 60 % (težinski) polietilen oksida.
1 an example is given of a plant or lay-out according to the present invention, starting from the slab 1 at the outlet of a continuous casting through a mould referred to as 10 . 
S obzirom na Sliku 1 dan je primjer postrojenja ili rasporeda uređaja prema predstavljenom izumu, koje počinje od slaba 1 na izlazu kontinuiranog lijevanja kroz kalup 10.
an extract of Ginkgo biloba complexed with phospholipids, for the manufacture of a medicament for treatment of neurodegenerative. diseases. 
ekstrakt Ginko biloba kompleksiran s fosfolipidima, naznačena time da je za medicinsko liječenje neurodegenerativnih bolesti.
or an OX40 agonist antibody. 
(vi) OX40 agonističkog antitijela.
A capsule according to any one of the preceding claims, wherein the lid is connected to the cup at the second end of the circumferential wall, and the inner space is at least partially filled with the extractable product. 
Kapsula prema jednom od prethodnih patentnih zahtjeva, pri čemu je poklopac (14) povezan na čašicu na drugom kraju obodnog zida (102), npr. na rub (104) u obliku prirubnice, i unutrašnji prostor je najmanje djelomično ispunjen proizvodom koji se može ekstrahirati.
s is selected from 1 and 2; and 
s se bira između 1 i 2; i
Haemostatic composite according to claim 1, wherein said haemostatic material is a fabric of oxidized cellulose. 
Hemostatski kompozit prema zahtjevu 13, naznačen time da je navedeni hemostatski materijal tkanina od oksidirane celuloze.
A combination for use according to claim 5 wherein the B2 agonist is formoterol fumarate. 
Kombinacija sukladno patentnom zahtjevu 5, naznačena time, da je B2 agonist formoterol fumarat.
liver diseases, which coincide with inflammatory, allergic and/or proliferative processes, (viii) gastrointestinal diseases, which coincide with inflammatory, allergic and/or proliferative processes, 
bolesti jetre, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima, (viii) gastrointestinalnih bolesti, koje se poklapaju s upalnim, alergijskim i/ili proliferativnim procesima,
providing or generating at least one candidate sequence which consists of an amino acid sequence modified by substituting, deleting, or adding one, two or several amino acid residues to an original amino acid sequence, wherein the original amino acid sequence is selected from the group consisting of SEQ ID NO: 344; 
(1) osiguravanja najmanje jednog slijeda kandidata koji ima aminokiselinski slijed modificiran zamjenom jednog ili dva aminokiselinska ostatka u izvornom aminokiselinskom slijedu, gdje se izvorni aminokiselinski slijed se bira iz skupine koju čine SEQ ID NO:41, 44, 46, 48 1 78;
A vaccine kit for concomitant or sequential administration comprising two multivalent immunogenic compositions for conferring protection in a host against diease caused by Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, Haemophilus influenzae and Neisseria meningitidis, said kit comprising a first container comprising: tetanus toxoid (TT), 
Cjepivni komplet za istodobnu ili uzastopnu primjenu, naznačen time što sadrži dva polivalentna imunogena pripravka za postizanje zaštite kod domačina protiv bolesti koje uzrokuju bakterije Bordetella pertussis, Clostridium tetani, Corynebacterium diphtheriae, te Haemophilus influenzae, gdje navedeni komplet sadrži prvi spremnik, koji sadrži: tetanusni toksoid (TT), t>&
The EtOAc layer is separated and the aqueous phase is extracted with a further portion of EtOAc. 
Sloj u EtOAc se odvoji, a vodenu fazu se ekstrahira s daljnjim obrokom EtOAc.
introducing into a mammal a detectable quantity of the preparation according to claim 4; and detecting the compound bound to one or more deposits selected from tau-aggregate deposits, beta-amyloid aggregate deposits, or alpha-synuclein aggregate deposits via diagnostic imaging. 
uvođenje u sisavca takve količine pripravka u skladu sa zahtjevom 8, koja se može detektirati; ostavljanje dovoljnog vremena za omogućavanje sjedinjavanja spoja formule I s naslagama tau-agregata; i detektiranje spoja sjedinjenog s jednom ili više naslaga tau-agregata.
The method according to claim 1, wherein the respiratory disease is selected from the group consisting of asthma, nocturnal asthma, exercise-induced asthma, chronic obstructive pulmonary diseases (COPD), chronic bronchitis, wheezy bronchitis, emphysema, respiratory tract infection, upper respiratory tract disease, rhinitis, and allergic and seasonal rhinitis. 
Uporaba prema zahtjevu 1, naznačena time, da je bolest dišnih puteva odabrana iz skupine koju čine astma, noćna astma, astma inducirana napornom vježbom, kronična opstrukcijska plućna bolest (COPD), kronični i hripavi bronhitis, emfizem, upala respiratornog trakta i bolest gornjeg respiratornog trakta, rinitis, alergijski i sezonski Tinitis.
An anhydrous crystalline form named form A according to claim 4 of a monophosphoric acid salt of the compound of Formula I: wherein the anhydrous crystalline form A has an X-ray powder diffraction pattern (XRPD) comprising at least 3 characteristic peaks, in terms of 2θ, selected from peaks at 13.7°, 15°, 16.8°, 21.3° and 22.4°; wherein, with respect to values of 2θ, such values for individual peaks can vary by ±0.4°, where either, using Bruker D8 Advance instrument, irradiation: Cu Ka at 30 kV, 40 mA, variable slit V12 mm, scan range 2 - 40° (2 theta value), scan rate 0.3 s per step or, using XDS2000 by Scintag instrument, irradiation: Cu Ka at 45 kV, 40 mA, divergence slice 3 mm and 2 mm, measuring slice: 0.3 mm and 0.2 mm, chopper 0.02 grd, scan time: 6 minutes with 3 minutes per frame, scan range: 2° - 35° or 40° (2 theta value) and scan rate 0.5°/min (2 theta value) can be used for the XRPD. 
"u H gdje bezvodni kristalinični oblik A ima uzorak rendgenske difrakcije praška (engl. X-ray powder diffraction pattern, XRPD) s barem 3 karakteristična vrha, s obzirom na 20, izabrana između vrhova na 13.7%, 15%,16.8", 21.3% 122.4"; gdje, s obzirom na vrijednosti 20, te vrijednosti za pojedinačne vrhove mogu varirati za +0.4*, gdje se za XRPD može koristiti ili Bruker D8 Advance uređaj, zračenje: Cu Ka na 30 kV, 40 mA, varijabilna pukotina V12 mm, raspon analize 2 - 40" (2 theta vrijednost), brzina analize 0.3 s po koraku ili,
a ferromagnetic non-conductive member provided on a surface of each of said nonmagnetic members, the surface facing the center axis side of said ring members; and 
što je površina svakog od ne-magnetskih članova (13) okrenuta prema središnjoj osnoj strani prstenastih članova
wherein R2 is a hydrogen atom, a cyano group, a fluorine atom, a chlorine atom, a methyl group, a fluoromethyl group, a difluoromethyl group, a trifluoromethyl group, a hydroxymethyl group, an ethyl group, a methoxy group, a fluoromethoxy group, a difluoromethoxy group, a trifluoromethoxy group, an ethoxy group, a 2-fluoroethoxy group, a 2-propyloxy group, a cyclopropylmethoxy group, a cyclobutylmethoxy group or a (tetrahydro-2H-pyran-4-yl)methoxy group. 
Spoj ili njegova farmaceutski prihvatljiva kisela adicijska sol prema zahtjevu 4, pri čemu R2 je vodikov atom, cijano skupina, fluorov atom, klorov atom, metilna skupina, fluorometilna skupina, difluorometilna skupina, trifluorometilna skupina, hidroksimetilna skupina, etilna skupina, metoksi skupina, fluorometoksi skupina, difluorometoksi skupina, trifluorometoksi skupina, etoksi skupina, 2-fluoroetoksi skupina, 2-propiloksi skupina, ciklopropilmetoksi skupina, ciklobutilmetoksi skupina ili (tetrahidro-2H-piran-4-il)metoksi skupina.
The gown according to claim/wherein sleeves are attached to the arm openings. 
Kuta prema zahtjevu 5, naznačena time, da su na otvorima za ruke pričvršćeni rukavi.
oxidizing a compound (a “sulfide compound”) of the formula 
(a) oksidaciju spoja (Â« sulfidni spoj Â«) formule
and R2, together with the nitrogen atom to which they are attached, form an 8 to 11 member spirodiamine, an 8 member bicyclodiamine, a 7 member spiroxamine, a piperidinyl optionally substituted with ethyl, or a four to six member cycloalkyl, optionally substituted with at least one of carboxamidyl, aminomethyl, methyl, (ethylamino)methyl, (dimethylamino)methyl, dimethylamino, (methylamino)methyl, and amino; and wherein 
i R2, zajedno s dušikovim atomom na koji su oni vezani, tvore 8 do 11 člani spirodiamin, 8 člani biciklodiamin, 7 člani spiroksamin, piperidinil po izboru supstituiran s etilom, ili četiri do šest člani cikloalkil, po izboru supstituiran s barem jednim iz niza koji čine karboksamidil, aminometil, metil, (etilamino)metil, (dimetilamino)metil, dimetilamino, (metilamino)metil, i amino; i pri čemu
The use according to claim 3 wherein the crystalline salt is 1:1 (R)-3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-3-cyclopentylpropanenitrile:phosphoric acid salt. 
Postupak pripreme soli prema bilo kojem od patentnih zahtjeva od 1 do 5 koji podrazumijeva kombiniranje (R)-3-(4-(7H-pirolo[2,3-d]pirimidin-4-il)-1H-pirazol-1-il)-3-ciklopentilpropan-nitrila sa maleinskom kiselinom, sumpornom kiselinom ili fosfornom kiselinom.
The pharmaceutically acceptable transdermal composition of any one of claims 6 to 11, wherein (i) the composition has about 0.5 to about 7.5 weight percent octanol; and/or (ii) the composition has about 0.25 to about 5 weight percent limonene. 
Farmaceutski prihvatljiv transdermalni sastav iz bilo kojeg zahtjeva od 6 do 11, naznačeno time da (i) sastav ima između otprilike 0,5 i otprilike 7,5 posto težine oktanola; i/ili (11) sastav ima između otprilike 0,25 1 otprilike 5 posto težine limonena.
the provision of a first magnetic pole; 
pripremu prvog magnetskog pola (2b, 8b);
Among the cancer types in which NGF has been proven effective in the state of the art, either in vivo or in vitro, due to improving effects on cell differentiation and cell survival, through either TrkA and/or p75 pathways, the following may be cited: glioblastoma, astrocytoma, meduloblastoma, neurinoma, neuroblastoma, meningioma, colon cancer, pancreatic cancer, breast cancer, prostate cancer, leukemia, acute lymphocytic leukemia, osteosarcoma, hepatocellular carcinoma, ovarian carcinoma, lung adenocarcinoma or esophagic carcinoma. 
HR P20160553 T1 glioblastom, astrocitom, meduloblastom, neurinom, neuroblastom, meningiom, rak kolona, rak gušterače, rak dojke, rak prostate, leukemija, akutna limfocitna leukemija, osteosarkom, hepatocelularni karcinom, karcinom jajnika, adenom pluća i karcinom jednjaka. Tvar za uporabu iz patentnog zahtjeva 5 ili farmaceutski sastav iz patentnog zahtjeva 6, pri čemu medikament ili farmaceutski sastav ima kombinaciju neuroprotektivnog i imunomodulatornog učinka.
The extended release tablet formulation according to any of the preceding claims, wherein the contained amount of pramipexole or pharmaceutically acceptable salt thereof is sufficient to provide a daily dose administered at one time. 
Formulacija tablete produljenog oslobađanja u skladu s bilo kojim prethodnim zahtjevom, naznačena time, da je sadržana količina pramipeksola ili njegove farmaceutski prihvatljive soli dovoljna da osigura dnevnu dozu primjenjenu odjednom.
An immunoconjugate comprising a cytotoxic agent and a human or humanized antibody or functional fragment thereof, wherein the cytotoxic agent is a maytansinoid or a derivative thereof, wherein the human or humanized antibody or functional fragment thereof comprises an antigen-binding site that is specific for Mesothelin (SEQ ID NO:36), the antigen-binding site comprising a variable heavy chain comprising complementarity determining regions (CDRs) corresponding to SEQ ID NOS 3, 6, and 9 and a variable light chain comprising CDRs corresponding to SEQ ID NOS 12, 15, and 19, wherein the human or humanized antibody or functional fragment thereof exhibits invariant binding of Mesothelin, and wherein the cytotoxic agent and the human or humanized antibody or functional fragment thereof are linked by SPDB. 
HR P20180015 T1 PATENTNI ZAHTJEVI Imunokonjugat koji sadrži citotoksično sredstvo i ljudsko ili humanizirano protutijelo ili njegov funkcionalni fragment, naznačen time da navedeno protutijelo ili njegov funkcionalni fragment sadrži regiju za vezanje antigena koja je specifična za Mezotelin (SEQ ID NO:36), te pri čemu mjesto vezanja protutijela uključuje CDR1, CDR2, i CDR3 pri čemu: a) -HCDRI je predstavljena sa SEQ ID NO: 3, b) HCDR2 je predstavljena sa SEQ ID NO: 6, c) -HCDR3 je predstavljena sa SEQ ID NO: 9, d) LCDRI je predstavljena sa SEQ ID NO: 12,
The process of claim 38, wherein the reaction mixture in step (c) comprises an organic solvent in which the byproduct M1-R3 has low solubility, selected from the group consisting of methylcyclohexane, cyclohexane, heptane, hexane, toluene, and mixtures thereof. 
Postupak prema patentnom zahtjevu 38, pri čemu reakcijska smjesa u koraku (c) sadrži organsko otapalo u kojem sporedni proizvod M-R> ima nisku otopljivost, izabran iz grupe koju čine metilcikloheksan, cikloheksan, heptan, heksan, toluen i njihove smjese.
This syndrome is often associated with opioid addiction, because many addicts cannot maintain their supply of opioids and do not de-escalate their dosing prior to running out of drug. 
Ovaj je sindrom često udružen s ovisnošću o opioidima jer mnogi ovisnici ne mogu održavati svoju opskrbljenost opioidima i ne smanjuju svoje doze prije nego ostanu bez droge.
There is also a growing body of evidence that PPARY agonist, insulin sensitizer, may have benefits in the treatment of Type II diabetes beyond their effects in improving glycemic control. 
Također je sve više dokaza da agonist PPARY i inzulinski sensitizator mogu povoljno djelovati u liječenju dijabetesa tip II i pored njihovih učinaka poboljšane kontrole šećere u krvi.
contacting a compound of Formula 4, 
(a) miješanju spoja Formule 4 I
A pharmaceutical composition comprising a sulphate salt according to any one of claims 1 to 6, or a pharmaceutically acceptable solvate thereof, and at least one pharmaceutically acceptable carrier, diluent, excipient and/or adjuvant. 
Farmaceutski sastav koji sadrži sulfatnu sol u skladu s bilo kojim od patentnih zahtjeva 1 do 6, ili njen farmaceutski prihvatljivi solvat, 1 barem jedan farmaceutski prihvatljivi nosač, diluent, ekscipijens i/ili adjuvans.
A method of treating erectile dysfunction (ED) in a subject comprising administering to the subject a 5-HT2A antagonist and a norepinephrine-dopamine reuptake inhibitor. 
Pripravak koji sadrži trazodon, bupropion, i farmaceutski prihvatljiv nosač naznačen time da je za uporabu za liječenje erektilne disfunkcije (ED) kod subjekta.
The kit of any of claims 59-60, further comprising a shampoo, a conditioner, instructions for use, a developer, mixing container, an odor eliminator, or a combination thereof. 
Komplet prema bilo kojem od zahtjeva 59-60, naznačen time da nadalje obuhvaća šampon, regenerator, upute za upotrebu, razvijač, posudu za miješanje, odstranjivač mirisa ili njihovu kombinaciju.
The PAM50 classification model described herein is based on the gene expression profile for a plurality of subject samples using the intrinsic genes listed in Table 1. 
(ill) profil ekspresije gena za ispitivani uzorak se dobiva analizom na mikročipu, uz pomoć sondi specifičnih za produkt ekspresije svakog od navedenih intrinzičnih gena; ili
A may be -X1- or -X1-OC(R9)(R10)-, in which may be an alkyl group having from 1 to 5 carbon atoms, optionally substituted with one or more alkyl groups having from 1 to 5 carbon atoms or one or more alkoxy groups having from 1 to 3 carbon atoms, and 
[image] u kojoj A može biti -X1- ili -X1-OC(R9)(R10)-, gdje može biti alkil-skupina koja ima od jednoga do pet atoma ugljika, opcijski supstituirana s jednom ili više alkil-skupina koje imaju od jednoga do pet atoma ugljika ili s jednom ili više alkoksi-skupina koje imaju od jednoga do tri atoma ugljika; i
A process according to claim 1, wherein R2 is alkyl optionally substituted with OH. 
Y je -CONRŽR* ili -CN; i R' je alkil, izborno supstituiran s OH.
The organic phases were washed with NH4Cl (sat.), dried over MgSO4, filtered and evaporated. 
Organske faze se isperu s NHLCI (zas.), osuše preko MgSO,, filtriraju i upare.
A compound according to claim 1, selected from the group consisting of: or a pharmaceutically acceptable salt, hydrate or solvate thereof. 
R* ili njegova farmaceuski prihvatljiva sol, hidrat ili solvat. Spoj u skladu s patentnim zahtjevom 1, naznačen time što ga se bira iz skupine koju čine: